Latigo Biotherapeutics (NASDAQ:LTGO) Shares Gap Up – What’s Next?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $21.40, but opened at $22.62. Latigo Biotherapeutics shares last traded at $22.32, with a volume of 2,557 shares.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th.

Latigo Biotherapeutics Stock Down 0.1%

Insider Transactions at Latigo Biotherapeutics

In other news, Director James B. Tananbaum purchased 140,000 shares of the stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the director owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.